Troutman Pepper Locke advised Ocugen, Inc. (Ocugen), a pioneering biotechnology leader in gene therapies for blindness diseases, in the execution of a licensing agreement with Kwangdong Pharmaceutical, Co., Ltd. (Kwangdong), one of the leading pharmaceutical companies in Korea, for the exclusive Korean rights to OCU400 — Ocugen’s novel modifier gene therapy for retinitis pigmentosa. For more information, see the press release.
There are an estimated 7,000 individuals in the Republic of Korea with retinitis pigmentosa, which represents approximately 7% of the U.S. market. OCU400 provides the opportunity for Kwangdong to help thousands of patients facing vision loss. Upon regulatory approval of OCU400 in Korea, Kwangdong will be positioned to become a leader in the field of ophthalmic gene therapy in Korea.
The Troutman Pepper Locke team that advised Ocugen included Debbie Spranger, Elizabeth-Ann Weeks, Mindy Rudolph, Emily Makar, Joan Arnold, Peter Jeydel, Judy O’Grady, and Barbara Sicalides.